Actinogen Medical Ltd (ASX: ACW) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Actinogen Limited. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $249.04 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.78 billion
Earnings per share -0.003
Dividend per share N/A
Year To Date Return -15.63%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Actinogen Medical Ltd (ASX: ACW)
Latest News

ACW ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Actinogen Medical Ltd

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

ACW Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 Jan 2022 $0.14 $0.01 7.41% 2,005,040 $0.14 $0.14 $0.13
19 Jan 2022 $0.14 $-0.01 -7.14% 1,718,836 $0.14 $0.15 $0.14
18 Jan 2022 $0.14 $-0.01 -6.67% 2,011,849 $0.16 $0.16 $0.14
17 Jan 2022 $0.15 $0.00 0.00% 262,329 $0.16 $0.16 $0.15
14 Jan 2022 $0.15 $0.00 0.00% 1,086,725 $0.15 $0.16 $0.15
13 Jan 2022 $0.15 $-0.01 -6.45% 1,242,267 $0.15 $0.16 $0.15
12 Jan 2022 $0.16 $-0.01 -6.25% 636,734 $0.16 $0.16 $0.15
11 Jan 2022 $0.16 $0.00 0.00% 276,902 $0.16 $0.16 $0.15
10 Jan 2022 $0.16 $0.00 0.00% 1,273,188 $0.16 $0.16 $0.15
07 Jan 2022 $0.16 $0.01 6.45% 753,627 $0.16 $0.16 $0.15
06 Jan 2022 $0.16 $-0.02 -11.76% 3,008,859 $0.17 $0.17 $0.15
05 Jan 2022 $0.17 $0.00 0.00% 2,690,527 $0.18 $0.18 $0.16
04 Jan 2022 $0.18 $0.02 12.50% 2,968,684 $0.17 $0.18 $0.16
31 Dec 2021 $0.16 $0.00 0.00% 2,801,743 $0.16 $0.16 $0.15
30 Dec 2021 $0.16 $0.01 6.67% 4,325,223 $0.15 $0.16 $0.15
29 Dec 2021 $0.15 $0.01 7.27% 2,575,829 $0.14 $0.15 $0.14
24 Dec 2021 $0.14 $0.00 0.00% 1,336,624 $0.14 $0.15 $0.14
23 Dec 2021 $0.14 $0.01 7.69% 1,723,741 $0.13 $0.14 $0.13
22 Dec 2021 $0.13 $0.00 0.00% 2,509,816 $0.13 $0.13 $0.13
21 Dec 2021 $0.13 $0.01 8.33% 1,559,243 $0.13 $0.13 $0.12

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Dec 2021 George Morstyn Issued 222 $30,000
Participation in share purchase plan.
20 Dec 2021 Malcolm McComas Issued 222 $30,000
Participation in share purchase plan.
20 Dec 2021 Geoffrey Brooke Issued 222 $30,000
Participation in share purchase plan.
18 Nov 2021 George Morstyn Issued 1 $200,000
Issued under employee share plan. Deemed issue price
18 Nov 2021 Geoffrey Brooke Issued 2 $500,000
Issued under employee share plan. Deemed issue price
18 Nov 2021 Malcolm McComas Issued 1 $200,000
Issued under employee share plan. Deemed issue price

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr George Morstyn Non-Executive Director Dec 2017
Dr Morstyn has more than 25 years experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had overall responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn was the principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (CSF). The CSFs were subsequently approved and launched and were a major medical breakthrough that have been used to reduce side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide. The CSFs have become multi-billion dollar drugs. Since returning to Australia, Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently an advisor to Symbio (Tokyo) Limos Biotech and TroBio.
Mr Malcolm John McComas Non-Executive Director Apr 2019
Mr McComas is a company director with experience in healthcare including drug development, clinical trials, the regulatory environment and medical devices. He was previously an investment banker with career experience in financial services covering mergers and acquisitions, debt and equity funding across multiple industry sectors including healthcare, FMCG, resources, financial services and privatisations. He has held leadership roles with Grant Samuel as Director, County NatWest (now Citigroup) as Managing Director and Head of Corporate Finance and Morgan Grenfell (now Deutsche Bank) working in Australia and the UK. Previously, Mr McComas was a lawyer at Herbert Geer specialising in tax and company law. He has for-purpose experience as a director of Australasian Leukaemia and Lymphoma Group (ALLG), the blood cancer clinical trials group and peak body experience as past President of the Financial Services Institute of Australia.
Dr Geoffrey E.D Brooke Non-Executive ChairmanNon-Executive Director Feb 2021
Dr Brooke have more than 30 years international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies with a realised value of more than $1.5 billion. Most notably, he was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures - one of Asia Pacific's premier investors in the healthcare space. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region and raised $450 million in venture and private equity funds, focused on biopharmaceuticals, medical devices and services. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of leading global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on founding companies based upon healthcare-related technology, including pharmaceuticals, biotechnology, therapeutic devices, medical services and information systems. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.
Dr Steven Gourlay Chief Executive OfficerManaging Director Mar 2021
Dr Gourlay has more than 30 years of experience in the development of novel therapeutics and brings skills and experience to Actinogen as the Company moves into further clinical development of its lead compound Xanamem. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a successful NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition by Sanofi for US$3.7 billion in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he contributed to the success of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a post doctorate in clinical pharmacology at the University of California, San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications.
Mr Peter Webse Company Secretary
Jeff Carter Chief Financial Officer
Peter Webse Company Secretary
Tamara Miller Vice President of Drug Development & Strategy

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 249,813,605 15.04%
Dr Steven Gourlay 48,362,300 2.91%
Edinburgh Technology Fund Limited 48,147,864 2.90%
JSC Wealth Management Pty Ltd 44,655,962 2.69%
Tisia Nominees Pty Ltd <Henderson Family A/C> 33,440,621 2.01%
Citicorp Nominees Pty Limited 19,464,401 1.17%
Garnsworthy Pension Fund Pty Ltd <Garnsworthy Pension Fund A/C> 16,500,000 0.99%
Big Eater Pty Ltd <Brigitte Smith Family A/C> 15,000,000 0.90%
Mr James Murch & Mrs Catherine Murch <MINJAL Super Fund A/C> 15,000,000 0.90%
SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> 15,000,000 0.90%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> 13,247,438 0.80%
Mrs Gillian Karen Nes & Mrs Ronald Nes <GIRO S/F A/C> 13,000,000 0.78%
Surfit Capital Pty Ltd 12,500,000 0.75%
Oaktone Nominees Pty Ltd <Grist Investment A/C> 12,000,000 0.72%
Brazil Farming Pty Ltd 12,000,000 0.72%
Double Jay Group Holdings Pty Ltd <Kimberley S/F A/C> 11,475,253 0.69%
National Nominees Limited 11,282,894 0.68%
Amber Court Nominees Pty Ltd <Min Light A/C> 11,265,203 0.68%
Kaleidoscope Holdings Pty Ltd <Kaleidoscope Super A/C> 10,800,000 0.65%
John Dahlsen Superannuation Fund Pty Ltd 10,411,036 0.63%